Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients. - Wikidata - awgldk - TriplyDB

Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients.

Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients.

http://www.wikidata.org/entity/Q42914779

about

Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.Optimizing dendritic cell-based approaches for cancer immunotherapy IFN-conditioned dendritic cells for the therapy of melanoma: what is missing?Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients.Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies.Polyfunctional Melan-A-specific tumor-reactive CD8(+) T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS.LAPTM4B-35 protein is a weak tumor-associated antigen candidate.Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy.Chemoimmunotherapy: reengineering tumor immunity.Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines.Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.Vaccines for established cancer: overcoming the challenges posed by immune evasion.The importance of correctly timing cancer immunotherapy.Quantitative analysis and clonal characterization of T-cell receptor β repertoires in patients with advanced non-small cell lung cancer treated with cancer vaccine.T Cell Receptor Profiling in Type 1 Diabetes.Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma.Immunological monitoring for prediction of clinical response to antitumor vaccine therapy.

P2860

Q26753070-2550EFA3-762D-46FC-B3ED-6960D7735292 Q26781215-72B43030-08A2-4242-AD2A-5D542FE06363 Q33665884-814E8091-9F26-44B8-B3FB-51FA04DF36BB Q34187201-EA17D8A4-351C-4C85-8F44-C631AE63DB02 Q34637535-348A4A47-9BAF-42F2-9FDC-73B1220A70C4 Q35250795-5BFD1BED-5505-4498-B0E7-3EE26C12D544 Q36057482-326197EB-F311-4F29-B263-58931DA78B77 Q36287976-70B6B513-2CAD-4105-BCFF-CBEA6B9DA6F1 Q37012650-7A59F0BE-879C-4103-93E1-A608A92BC181 Q37434480-F634B619-56F6-48A0-8313-FBC83DFAF327 Q37969356-352CAEA1-1561-4613-B5D6-3686E71A878D Q38079749-2C90BFBB-222C-4E2C-A170-B9A6B2CB909F Q38115968-0387B9CF-44CD-4A86-9158-373415A9BB2D Q38161367-A8370068-8145-45AB-B914-DDCC7540DEFA Q38730989-423FB7B9-B19A-4129-A25C-2144FBB512DF Q38769021-80E99CBA-4B04-4431-8BB2-3F4FADC3AFB9 Q38995979-67B0FDFA-0077-49DA-B343-16535E5F478A Q40978230-67596D88-3143-4363-9938-CD8127827370 Q42374922-076B515F-A505-453F-9739-B6CF72FE716C Q47135720-C5209F1D-38F5-4766-B1F0-42F0256F282A Q55046017-A37F79B5-DF47-4569-8C42-0002CEE32802

P2860

Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients.

http://www.wikidata.org/entity/Q42914779

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Dacarbazine treatment before p ...... tive CTL in melanoma patients.

@en

Dacarbazine treatment before p ...... tive CTL in melanoma patients.

@nl

type

label

Dacarbazine treatment before p ...... tive CTL in melanoma patients.

@en

Dacarbazine treatment before p ...... tive CTL in melanoma patients.

@nl

prefLabel

Dacarbazine treatment before p ...... tive CTL in melanoma patients.

@en

Dacarbazine treatment before p ...... tive CTL in melanoma patients.

@nl

P1433

Q42914779-CAD44772-B36E-4F79-B402-E29659BB02FD

P1476

Q42914779-8F3C4458-C86D-4B44-A8E6-798E894967EC

P2093

Q42914779-04487BDE-94CB-47A5-B983-5AE8221B3A17

Q42914779-12A9CFF3-7152-420C-B1B6-86A29A9DBA86

Q42914779-4F90CEE4-CA09-4D08-958B-EBBECF082509

Q42914779-54A11AEC-1A82-4194-8774-595612D391B7

Q42914779-9F5E1F2D-B7CF-412B-BE27-7E08A54235E5

Q42914779-A520CB51-46E0-40DB-81C3-D4E5ABD640B6

Q42914779-A96203CF-E9DB-447C-BD52-ED726E719DC8

Q42914779-AF525672-10F7-4D91-B8D5-EDB5BA7B09F6

Q42914779-C9AA7D42-3C18-4283-AA60-DBEBDD78FF4A

P304

Q42914779-E5C5D2AC-6918-481A-B5A4-2AE9653DFA5C

P31

Q42914779-83852414-CA73-48F6-BA55-E3D9B330BAD6

P356

Q42914779-9701009C-250E-4E39-A33A-D2E63E291C61

P407

Q42914779-70ABA7AA-C5F3-491F-8477-895F38B6027C

P433

Q42914779-A189EBF2-E80C-4ACF-AD31-BC5EA61FEE5F

P478

Q42914779-98CB7F0A-D1C3-41B3-8943-D05E1CBAD6ED

P50

Q42914779-2F41AA76-C154-46B1-8357-29D45D2A7393

Q42914779-A2645ADA-0333-4636-A6A6-B646C2227110

Q42914779-D5D8242C-49DE-4538-BC02-E0F2F6636316

Q42914779-EB4639F9-B8A1-45FB-A0FD-2065FA98293F

P577

Q42914779-CBEBC348-BA39-47C3-ABAC-1E75C37B358F

P698

Q42914779-E7DFE9F5-A0A5-47E5-8005-F63287699B87

P356

0008-5472.CAN-10-1326

P1433

Cancer Research

P1476

Dacarbazine treatment before p ...... ctive CTL in melanoma patients

@en

P2093

Alessandra Sottini

http://www.w3.org/2001/XMLSchema#string

Belinda Palermo

http://www.w3.org/2001/XMLSchema#string

Caterina Catricalà

http://www.w3.org/2001/XMLSchema#string

Claudia Ghidini

http://www.w3.org/2001/XMLSchema#string

Duilia Del Bello

http://www.w3.org/2001/XMLSchema#string

Federico Serana

http://www.w3.org/2001/XMLSchema#string

Luisa Imberti

http://www.w3.org/2001/XMLSchema#string

Novella Gualtieri

http://www.w3.org/2001/XMLSchema#string

Pier Giorgio Natali

http://www.w3.org/2001/XMLSchema#string

P304

7084-7092

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-10-1326

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Filippo Belardelli

Enrico Proietti

Virginia Ferraresi

P577

2010-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20823160

http://www.w3.org/2001/XMLSchema#string